Abstract
Introduction: The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to add to previous evidence by investigating body mass index (BMI) alongside CT derived body composition metrics in the largest cohort to date.
Method: Patients treated with first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were retrospectively identified from 11 melanoma reference centers in The Netherlands. Age, sex, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase, presence of brain and liver metastases, number of affected organs and BMI at baseline were extracted from electronic patient files. From baseline CT scans, five body composition metrics were automatically extracted: skeletal muscle index, skeletal muscle density, skeletal muscle gauge, subcutaneous adipose tissue index and visceral adipose tissue index. All predictors were correlated in uni- and multivariable analysis to progression-free, overall and melanoma-specific survival (PFS, OS and MSS) using Cox proportional hazards models.
Results: A total of 1471 eligible patients were included. Median PFS and OS were 8.8 and 34.8 months, respectively. A significantly worse PFS was observed in underweight patients (multivariable HR=1.87, 95% CI 1.14–3.07). Furthermore, better OS was observed in patients with higher skeletal muscle density (multivariable HR=0.91, 95% CI 0.83-0.99) and gauge (multivariable HR=0.88, 95% CI 0.84-0.996), and a worse OS with higher visceral adipose tissue index (multivariable HR=1.13, 95% CI 1.04-1.22). No association with survival outcomes was found for overweightness or obesity and survival outcomes, or for subcutaneous adipose tissue.
Discussion: Our findings suggest that underweight BMI is associated with worse PFS, whereas higher skeletal muscle density and lower visceral adipose tissue index were associated with better OS. These associations were independent of previously identified predictors, including sex, age, performance status and extent of disease. No significant association between higher BMI and survival outcomes was observed.
Introduction
Immune checkpoint inhibitors (ICIs), specifically anti-PD1 and anti-CTLA4 therapies, have fundamentally changed the prognosis for patients with advanced melanoma. Despite these advancements, a significant portion of patients do not achieve a durable response. Identifying reliable biomarkers to predict treatment outcomes remains a clinical priority.
One area of intense interest is the "obesity paradox"—the observation in some studies that patients with a high Body Mass Index (BMI) experience improved survival when treated with ICIs. However, BMI is a limited metric that fails to distinguish between muscle mass and adipose tissue distribution. This study, the largest of its kind to date, utilizes deep-learning-based CT analysis to investigate whether specific body composition phenotypes—such as muscle quality and visceral fat—provide more precise prognostic value than BMI alone.
Methods
This retrospective cohort study analyzed 1,471 patients with unresectable stage IIIC or IV cutaneous melanoma treated with first-line immunotherapy across 11 reference centers in the Netherlands between 2016 and 2023.
To move beyond the limitations of BMI, researchers employed automated CT segmentation using a deep-learning algorithm (Quantib Body Composition). This tool analyzed baseline CT scans at the third lumbar (L3) vertebra level to extract five distinct metrics:
- Skeletal Muscle Index (SMI): A measure of muscle quantity.
- Skeletal Muscle Density (SMD): A measure of muscle quality (lower density indicates fat infiltration, or myosteatosis).
- Skeletal Muscle Gauge (SMG): The product of muscle area and density.
- Subcutaneous Adipose Tissue Index (SATI): Fat stored under the skin.
- Visceral Adipose Tissue Index (VATI): Fat stored around internal organs.
Statistical analyses utilized Cox proportional hazards models, adjusting for established clinical variables including age, sex, LDH levels, and the presence of brain or liver metastases.
Key Insights and Results
Challenging the Obesity Paradox
Contrary to several earlier, smaller-scale studies, this large-scale analysis found no significant survival advantage for patients classified as overweight or obese. This suggests that the previously reported "obesity paradox" may have been influenced by smaller sample sizes or insufficient adjustment for confounding clinical factors.
The Risk of Underweight Status
While high BMI did not confer a benefit, low BMI was a clear risk factor. Underweight patients (BMI < 18.5) faced a significantly higher risk of disease progression, with a multivariable Hazard Ratio (HR) of 1.87 for progression-free survival (PFS). This may reflect a state of cachexia or lower physical reserves to withstand the demands of advanced disease and treatment.
Muscle Quality vs. Quantity
Interestingly, the total area of muscle (SMI) was not a significant predictor of survival. However, muscle quality (SMD and SMG) was highly relevant. Higher skeletal muscle density was protective (HR = 0.91 per SD increase), suggesting that the health and composition of the muscle tissue are more critical for survival than the volume of muscle alone.
The Role of Visceral Fat
The study highlighted a critical distinction between types of adipose tissue. While subcutaneous fat had no impact on outcomes, high levels of visceral fat (VATI) were associated with worse overall survival (HR = 1.13 per SD increase). Visceral fat is metabolically active and pro-inflammatory, potentially creating an environment that dysregulates the immune response required for ICI efficacy.
Discussion and Clinical Implications
The findings demonstrate that body composition metrics provide prognostic information independent of known clinical predictors like performance status and disease extent. The association between high visceral fat and poor outcomes suggests that the pro-inflammatory nature of visceral adiposity may interfere with T-cell activity, though the exact biological mechanisms require further study.
While the study is limited by its retrospective nature and the technical challenges of normalizing contrast-enhanced vs. non-contrast CT scans, its scale provides robust evidence that clinicians should look beyond BMI. Identifying patients with low muscle quality or high visceral fat may help in personalizing care and understanding the biological drivers of treatment resistance in advanced melanoma.
Summary updated